Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZAR: datopotamab deruxtecan + durvalumab + carboplatin versus pembrolizumab + platinum-based chemotherapy in first-line advanced NSCLC
2021-004606-21Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Aug 2022; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004606-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004606-21.